Highlighting Gaps in Testing and Diagnosis for Fragile X Syndrome: Craig A. Erickson, MD – Neurology Live

Fragile X syndrome (FXS) remains frequently underdiagnosed due to significant gaps in clinical testing and provider awareness, according to Dr. Craig A. Erickson. As detailed by Neurology Live, these diagnostic delays prevent patients from accessing targeted interventions and support systems essential for managing the genetic condition.

Fragile X syndrome is the most common inherited cause of intellectual disability and autism. It occurs when the FMR1 gene on the X chromosome is silenced, typically through an expansion of CGG repeats, which prevents the production of the fragile X mental retardation protein (FMRP). According to the National Organization for Rare Disorders (NORD), this protein is critical for normal brain development and synaptic plasticity.

Barriers to Fragile X Diagnosis

Dr. Craig A. Erickson identifies a persistent lack of routine screening as a primary obstacle to timely diagnosis. Many patients present with developmental delays or behavioral challenges that overlap with other neurodevelopmental disorders, leading clinicians to overlook FXS in favor of more common diagnoses like non-specific autism spectrum disorder, according to Neurology Live.

The diagnostic process often relies on the clinician’s decision to order a specific genetic test. Because FXS is not always included in standard newborn screening or general developmental panels, patients may undergo years of evaluations without receiving a definitive genetic explanation for their symptoms.

The Role of FMR1 Genetic Testing

Diagnosis requires molecular genetic testing to determine the number of CGG repeats in the FMR1 gene. According to the Centers for Disease Control and Prevention (CDC), the population is generally categorized into three groups based on these repeats: normal, premutation, and full mutation.

• Normal: Individuals with 55 to 44 repeats.
• Premutation: Individuals with 55 to 200 repeats, who may not show intellectual disability but are at risk for Fragile X-associated tremor/ataxia syndrome (FXTAS) or primary ovarian insufficiency.
• Full Mutation: Individuals with more than 200 repeats, resulting in the silencing of the FMR1 gene and the clinical manifestation of FXS.

Dr. Erickson emphasizes that identifying premutation carriers is as vital as diagnosing those with the full mutation. This allows for family planning and the monitoring of adult-onset conditions that affect carriers who do not have the full syndrome.

Clinical Implications of Delayed Detection

Missing a Fragile X diagnosis impacts the precision of therapeutic interventions. According to Neurology Live, a confirmed diagnosis allows providers to tailor behavioral therapies and pharmacological treatments to the specific neurobiological profile of FXS, rather than relying on generalized approaches for intellectual disability.

Early detection is linked to better outcomes in speech and language therapy and the implementation of structured environmental supports. When the genetic cause is unknown, families often face a “diagnostic odyssey,” spending years seeking answers while the child misses critical early intervention windows.

Improving Screening Protocols

To close these gaps, medical professionals are encouraged to recognize specific red flags. According to the CDC, physical markers such as a long face, large ears, and hyper-extensible joints, combined with social anxiety or gaze avoidance, should prompt immediate FMR1 testing.

Dr. Erickson suggests that increasing the integration of genetic testing into the standard of care for all children with unexplained intellectual disability or autism could reduce the current diagnostic lag. This shift would move FXS from a “suspected” diagnosis based on phenotype to a confirmed diagnosis based on genotype.

–>